Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
32-Week RCT of Semaglutide vs Tirzepatide in Non-diabetic Obesity
jRCT1031260243Not yet recruiting
- Start
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Randomised trial in obesity comparing Semaglutide arm with Tirzepatide arm (2 arms). Primary endpoint: Oxidative stress marker (d-ROMs). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on jRCT1031260243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031260243.